Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | CDK7 | P50613 | 17/20 | 0.70 |
| ▸ | CCNH | P51946 | 12/20 | 0.70 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.70 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.70 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.70 |
| ▸ | CDK1 | P06493 | 2/20 | 0.70 |
| ▸ | CDK2 | P24941 | 2/20 | 0.70 |
| ▸ | CDK9 | P50750 | 2/20 | 0.70 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.70 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.70 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.70 |
| ▸ | CCNK | O75909 | 1/20 | 0.70 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.70 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.70 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.70 |
| ▸ | CDK8 | P49336 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17140880 | 0.92 | EGFR (0.69) | EGFRCDK7CCNHCDK5CDK13 | |
| SCHEMBL20416126 | 0.91 | EGFR (0.71) | EGFRCDK7CCNHCDK5CDK13 | |
| SCHEMBL31425020 | 0.88 | EGFR (0.71) | EGFRCDK7CCNHCDK5CDK13 | |
| SCHEMBL18313560 | 0.88 | EGFR (0.87) | EGFRCDK7CCNHCDK5CDK13 | |
| SCHEMBL15648488 | 0.87 | CDK5 (0.71) | EGFRCDK7CCNHCDK5CDK13 | |
| SCHEMBL20204764 | 0.86 | CDK7 (0.74) | EGFRCDK7CCNHCDK5CDK13 | |
| SCHEMBL20204769 | 0.86 | CDK7 (0.81) | EGFRCDK7CCNHCDK5CDK13 | |
| SCHEMBL15647409 | 0.86 | PIP4K2C (0.53) | EGFRCDK7CCNHCDK5CDK13 | |
| SCHEMBL23609218 | 0.86 | CDK7 (0.77) | EGFRCDK7CCNHCDK5CDK13 | |
| SCHEMBL21561642 | 0.86 | CDK7 (0.71) | EGFRCDK7CCNHCDK5CDK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220390432-A1 | METHODS OF CHARACTERIZING AND UTILIZING AGENT-CONDENSATE INTERACTIONS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2022-12-08 | — | — | US | disclosed |
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-11 | — | — | US | disclosed |
| EP-3569598-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | Dana Farber Cancer Institute, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190346454-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018098473-A1 | REAGENTS AND METHODS FOR ANALYSIS OF PROTEINS AND METABOLITES TARGETED BY COVALENT PROBES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | EGFR 3656/4885CDK7 2189/4885CCNH 2179/4885 |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | EGFR 3656/4885CDK7 2189/4885CCNH 2179/4885 |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | PTMS, SRMS, HSP90B1 | EGFR 3656/4885CDK7 2189/4885CCNH 2179/4885 |
| US-20190346454-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | PTMS, SRMS, HSP90B1 | EGFR 3656/4885CDK7 2189/4885CCNH 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.